Cargando…
Targeted therapy in severe asthma today: focus on immunoglobulin E
Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed fo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500555/ https://www.ncbi.nlm.nih.gov/pubmed/28721017 http://dx.doi.org/10.2147/DDDT.S130743 |
_version_ | 1783248652171476992 |
---|---|
author | Pelaia, Girolamo Canonica, Giorgio Walter Matucci, Andrea Paolini, Rossella Triggiani, Massimo Paggiaro, Pierluigi |
author_facet | Pelaia, Girolamo Canonica, Giorgio Walter Matucci, Andrea Paolini, Rossella Triggiani, Massimo Paggiaro, Pierluigi |
author_sort | Pelaia, Girolamo |
collection | PubMed |
description | Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes current knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma. |
format | Online Article Text |
id | pubmed-5500555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55005552017-07-18 Targeted therapy in severe asthma today: focus on immunoglobulin E Pelaia, Girolamo Canonica, Giorgio Walter Matucci, Andrea Paolini, Rossella Triggiani, Massimo Paggiaro, Pierluigi Drug Des Devel Ther Review Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes current knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma. Dove Medical Press 2017-06-29 /pmc/articles/PMC5500555/ /pubmed/28721017 http://dx.doi.org/10.2147/DDDT.S130743 Text en © 2017 Pelaia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Pelaia, Girolamo Canonica, Giorgio Walter Matucci, Andrea Paolini, Rossella Triggiani, Massimo Paggiaro, Pierluigi Targeted therapy in severe asthma today: focus on immunoglobulin E |
title | Targeted therapy in severe asthma today: focus on immunoglobulin E |
title_full | Targeted therapy in severe asthma today: focus on immunoglobulin E |
title_fullStr | Targeted therapy in severe asthma today: focus on immunoglobulin E |
title_full_unstemmed | Targeted therapy in severe asthma today: focus on immunoglobulin E |
title_short | Targeted therapy in severe asthma today: focus on immunoglobulin E |
title_sort | targeted therapy in severe asthma today: focus on immunoglobulin e |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500555/ https://www.ncbi.nlm.nih.gov/pubmed/28721017 http://dx.doi.org/10.2147/DDDT.S130743 |
work_keys_str_mv | AT pelaiagirolamo targetedtherapyinsevereasthmatodayfocusonimmunoglobuline AT canonicagiorgiowalter targetedtherapyinsevereasthmatodayfocusonimmunoglobuline AT matucciandrea targetedtherapyinsevereasthmatodayfocusonimmunoglobuline AT paolinirossella targetedtherapyinsevereasthmatodayfocusonimmunoglobuline AT triggianimassimo targetedtherapyinsevereasthmatodayfocusonimmunoglobuline AT paggiaropierluigi targetedtherapyinsevereasthmatodayfocusonimmunoglobuline |